Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

被引：0

作者：

Markova, Alina ^{[1
]}

Papadopoulos, Esperanza B. ^{[2
]}

Dusza, Stephen ^{[1
]}

Ostojic, Jelena ^{[3
]}

Ai, Rizi ^{[3
]}

Maier, Tara ^{[1
]}

Lacouture, Mario ^{[1
]}

Tamari, Roni

Gyurkocza, Boglarka

Shaffer, Brian C. ^{[2
]}

Scordo, Michael ^{[2
]}

Perales, Miguel-Angel ^{[2
]}

Harris, Andrew ^{[4
]}

Ponce, Doris M. ^{[2
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY USA

[3] DermTech, San Diego, CA USA

[4] Mem Sloan Kettering Canc Ctr, Dept Pediat, Pediat Stem Cell Transplantat & Cellular Therapie, New York, NY USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182198

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients With Chronic Myelomonocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 18 - 19
[2] Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia
Padron, Eric
DeZern, Amy E.
Niyongere, Sandrine
Ball, Markus Christian
Balasis, Maria
Ramadan, Hanadi
Lancet, Jeffrey E.
List, Alan F.
Mesa, Ruben A.
Roboz, Gail J.
Steensma, David P.
Sekeres, Mikkael A.
Komrokji, Rami S.
BLOOD, 2017, 130
[3] CLINICAL RESPONSE OF PATIENTS ON TOPICAL RUXOLITINIB FOR ACUTE AND CHRONIC GVHD
Hudda, Zahra
Flannery, Amanda
Teusink-Cross, Ashley
Khandelwal, Pooja
PEDIATRIC BLOOD & CANCER, 2023, 70 : S203 - S204
[4] Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD
Hudda, Zahra
Flannery, Amanda
Teusink-Cross, Ashley
Davies, Stella M.
Khandelwal, Pooja
BONE MARROW TRANSPLANTATION, 2024, 59 (03) : 425 - 427
[5] Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD
Zahra Hudda
Amanda Flannery
Ashley Teusink-Cross
Stella M. Davies
Pooja Khandelwal
Bone Marrow Transplantation, 2024, 59 : 425 - 427
[6] Promising efficacy and safety profile of ruxolitinib in highly pre-treated chronic GvHD patients
Lupo-Stanghellini, M. T.
Corti, C.
Guggiari, E.
Forcina, A.
Pavesi, F.
Brambilla, M.
Antonarelli, G.
Greco, R.
Assanelli, A.
Marktel, S.
Sala, E.
Perini, T.
Lorentino, F.
Giglio, F.
Mannina, D.
Xue, E.
Piemontese, S.
Dalto, S. C.
Messina, C.
Morelli, M.
Mastaglio, S.
Carrabba, M.
Lunghi, F.
Marcatti, M.
Vago, L.
Bonini, C.
Bernardi, M.
Peccatori, J.
Ciceri, F.
BONE MARROW TRANSPLANTATION, 2017, 52 : S229 - S230
[7] Lupuzor™ demonstrates promising results in Phase IIb clinical trial
不详
IMMUNOTHERAPY, 2010, 2 (01) : 7 - 7
[8] Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial
Padron, Eric
Tinsley-Vance, Sara M.
DeZern, Amy E.
Carraway, Hetty E.
Luskin, Marlise R.
Roboz, Gail J.
Chan, Onyee
Horton, Meagan
Gerds, Aaron T.
Sallman, David A.
Kuykendall, Andrew
Steensma, David
Balasis, Maria E.
Lancet, Jeffrey E.
Sekeres, Mikkael A.
Komrokji, Rami S.
BLOOD, 2022, 140 : 1101 - 1103
[9] Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial
Spaner, David E.
Wang, Guizhei
McCaw, Lindsay
Li, Yanmei
Disperati, Patricia
Cussen, Mary-Ann
Shi, Yonghong
HAEMATOLOGICA, 2016, 101 (05)
[10] Topical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial
Jinnin, Masatoshi
Shimokawa, Toshio
Kishi, Akiko
Hayashi, Nobukazu
Nagahama, Michiko
Kubo, Akiharu
Ozeki, Michio
Shimada, Shuichi
Fukushima, Satoshi
Kawabata, Tomotaka
Okuyama, Tomoki
Okubo, Aki
Sawai, Yumika
Hayashi, Ayato
Kurimoto-Nishiguchi, Mana
Sakata, Mariko
Kunimoto, Kayo
Yamamoto, Yuki
JOURNAL OF DERMATOLOGY, 2025,

← 1 2 3 4 5 →